GB2371622A - Susceptibility gene for inflammatory bowel disease - Google Patents

Susceptibility gene for inflammatory bowel disease Download PDF

Info

Publication number
GB2371622A
GB2371622A GB0206993A GB0206993A GB2371622A GB 2371622 A GB2371622 A GB 2371622A GB 0206993 A GB0206993 A GB 0206993A GB 0206993 A GB0206993 A GB 0206993A GB 2371622 A GB2371622 A GB 2371622A
Authority
GB
United Kingdom
Prior art keywords
ibd
inflammatory bowel
disease
bowel disease
ulcerative colitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0206993A
Other versions
GB0206993D0 (en
Inventor
Derek Parry Jewell
Jon David Simmons
Jack Satsangi
Kenneth Ian Welsh
Lee R Brettman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of GB0206993D0 publication Critical patent/GB0206993D0/en
Publication of GB2371622A publication Critical patent/GB2371622A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

An association between a 32bp deletion in the human gene encoding chemokine receptor CCR5 and the development of inflammatory bowel disease. (IBD), in particular Crohn's disease and ulcerative colitis is described. Methods of diagnosis of susceptibility to IBD and of distinguishing between Crohn's disease and ulcerative colitis are provided which involve detection of the CCR5- W 32 allele in patients suffering from, or suspected of developing. IBD. Screening methods suitable for identifying molecules with potential as therapeutic agents against IBD are also described.

Description

,,UK Patent Application, g,GB.,2 371 622 {13JA (43) Date of Printing by UK
Office 31.07.2002 (21) Application No 0206993.8 (51) INTCL7 C12Q 1/68, GOlN 33/50 // A61K 39/00 (22) Date of Filing 23.09.1999 (52) UK CL (Edition T) (86) International Application Data G1B BAC B223 PCT/GBg9/03192 En 23.09.1999 U1S S1318 (87) International Publication Data (56) Documents Cited by ISA WO01/21832 En 29.03.2001 WO 99/32100 A WO 98/34945 A Gastroenterology, April l999r Vol. 116, No. 4, page (71) Applicant(s) a821 Isis Innovation Limited Nature, 1996, Vol. 382, No. 6593, pages 722-725 llacorPorated in the Umted Kingdoml Ewert House, Ewert Place, Summertown, OXFORD, (58) Field of Search by ISA
OX2 7BZ, United Kingdom INT CL7 A61K, C12Q, GOlN EPO-lntemal, WPI Data, PAJ, MEDLINE, BIOSIS (72) Inventor(s) EMBASE, CHEM ABS Data Derek Parry Jewell Jon David Simmons Jack Satsangi 174) Agent and/or Address for Service Kenneth lan Welsh Boult Wade Tennant Lee R Brettman Vsrulam Gardens, 70 Gray's Inn Road, LONDON, WC1X 8BT, United Kingdom (54) Abstract Title Susceptibility gene for inflammatory bowel disease (57) An association between a 32bp deletion in the human gene encoding chemokine receptor CCR5 and the development of inflammatory bowel disease. (iBD), in particular Crohn's disease and ulcerative colitis is described. Methods of diagnosis of susceptibility to IBD and of distinguishing between Crohn's disease and ulcerative colitis are provided which involve detection of the CCR5-Q32 allele in patients suffering from, or suspected of developing, IBD. Screening methods suitable for identifying molecules with potential as therapeutic agents against IBD are also described.
G) W CD D
GB0206993A 1999-09-23 1999-09-23 Susceptibility gene for inflammatory bowel disease Withdrawn GB2371622A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1999/003192 WO2001021832A1 (en) 1999-09-23 1999-09-23 Susceptibility gene for inflammatory bowel disease

Publications (2)

Publication Number Publication Date
GB0206993D0 GB0206993D0 (en) 2002-05-08
GB2371622A true GB2371622A (en) 2002-07-31

Family

ID=10847634

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0206993A Withdrawn GB2371622A (en) 1999-09-23 1999-09-23 Susceptibility gene for inflammatory bowel disease

Country Status (4)

Country Link
AU (1) AU6104699A (en)
CA (1) CA2385381A1 (en)
GB (1) GB2371622A (en)
WO (1) WO2001021832A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101943311B (en) * 2010-08-23 2012-12-26 广东爵仕泳池水疗设备有限公司 Multifunctional TV mount
RU2563172C1 (en) * 2014-11-12 2015-09-20 Общество с ограниченной ответственностью "Покровский банк стволовых клеток" METHOD FOR DETERMINING CCR5 delta 32 ALLELE POLYMORPHISM

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032019A2 (en) * 1996-03-01 1997-09-04 Euroscreen S.A. C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses
WO1998005798A1 (en) * 1996-08-08 1998-02-12 The Aaron Diamond Aids Research Center Hiv coreceptor mutants
WO1998034945A1 (en) * 1997-02-06 1998-08-13 Epoch Pharmaceuticals, Inc. Targeted modification of the ccr-5 gene
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032019A2 (en) * 1996-03-01 1997-09-04 Euroscreen S.A. C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses
WO1998005798A1 (en) * 1996-08-08 1998-02-12 The Aaron Diamond Aids Research Center Hiv coreceptor mutants
WO1998034945A1 (en) * 1997-02-06 1998-08-13 Epoch Pharmaceuticals, Inc. Targeted modification of the ccr-5 gene
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gastroenterology, April 1999, Vol. 116, No. 4, page a821 *
Nature, 1996, Vol. 382, No. 6593, pages 722-725 *

Also Published As

Publication number Publication date
CA2385381A1 (en) 2001-03-29
GB0206993D0 (en) 2002-05-08
WO2001021832A1 (en) 2001-03-29
AU6104699A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
Toleman et al. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes
Jin et al. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4* 1B and 3A5* 3 for 25 fentanyl cases
McQueen et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q
Nunes et al. Acute and chronic effects of clofibrate and clofibric acid on the enzymes acetylcholinesterase, lactate dehydrogenase and catalase of the mosquitofish, Gambusia holbrooki
Yang et al. Siderophore production by Pseudomonas pseudomallei
Šlajpah et al. Sixteen novel mutations identified in COL4A3, COL4A4, and COL4A5 genes in Slovenian families with Alport syndrome and benign familial hematuria
Aguillón et al. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution?
Ko et al. Melioidosis outbreak after typhoon, southern Taiwan
Wyer et al. Evaluating short-term changes in recreational water quality during a hydrograph event using a combination of microbial tracers, environmental microbiology, microbial source tracking and hydrological techniques: a case study in Southwest Wales, UK
Fiorillo et al. Two distinctive HLA haplotypes harbor the B27 alleles negatively or positively associated with ankylosing spondylitis in Sardinia: implications for disease pathogenesis
Conway et al. The Roles of Valine 208 and Histidine 211 in Ligand Binding and Receptor Function of the Ovine Mel1aβMelatonin Receptor
Bostanci et al. Tumor necrosis factor-α-converting enzyme (TACE) levels in periodontal diseases
Lombard et al. HLA class II disease associations in southern Africa
Ettinger et al. Allelic variation in key peptide-binding pockets discriminates between closely related diabetes-protective and diabetes-susceptible HLA-DQB1* 06 alleles
Du et al. Association of the CTLA-4 gene with Vogt–Koyanagi–Harada syndrome
Karl et al. Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats
Paul et al. Production of extracellular nucleic acids by genetically altered bacteria in aquatic-environment microcosms
Rao et al. 29 False positives and false negatives in genome scans
Xu et al. Evidence for the effect of gender on activity of (S)-mephenytoin 4’-hydroxylase (CYP2C19) in a Chinese population
Fournier et al. Detection of microsporidia, cryptosporidia and giardia in swimming pools: a one-year prospective study
Kidsley et al. Genomic analysis of fluoroquinolone-susceptible phylogenetic group B2 extraintestinal pathogenic Escherichia coli causing infections in cats
Shimoda et al. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position− 2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia
Donoghue et al. The distribution and origins of ancient leprosy
GB2371622A (en) Susceptibility gene for inflammatory bowel disease
Wolfram et al. Conserved low-affinity nickel-binding amino acids are essential for the function of the nickel permease NixA of Helicobacter pylori

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)